A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects with Locally Advanced or Metastatic Solid Tumors
Phase: Phase I-II clinical trials
Principal Investigator: Dott. Duca Matteo
Main Facility: Unità Studi Clinici di Fase 1 (Early clinical Drug Development Team-ECDD)
Drug: HER3-DXd
Pathologies: Advanced Solid Tumours, Melanoma, Pancreatic cancer, Lung cancer, Breast cancer, Endometrial cancer, Esophageal tumors, Cervical tumor, Prostate tumors, Head and neck cancers, Ovarian tumors, Urological cancers (kidney, bladder, urinary tract, others)
ClinicalTrials.gov: Read the details about clinical trials
Phase 2 study designed to assess the safety and efficacy of HER3-DXd monotherapy in subjects with refractory locally advanced unresectable or metastatic solid tumors that have been previously treated with ≥1 prior line of systemic anticancer therapy.
Last update: 21/04/2026